Meeting ReportDiabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
KEYWORDS
Cited by (0)
DdZ declared having served as a consultant for and received honoraria (to employer) from Abbott, AbbVie, Astellas, ChemoCentryx, Johnson & Johnson, Merck Sharp & Dohme, Pfizer, and Reata. CEM declaring having received speaker honoraria from Merck Sharp & Dohme. MEM declared having received consultancy fees from Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, and Novo Nordisk, and research funding from Bayer, Novartis, and Novo Nordisk. CW declared having received speaker honoraria from Astellas (Japan), Pfizer, Merck, and Merck Sharpe & Dohme. DCW declared having received consultancy fees from Abbvie, Amgen, Astellas, Baxter, F Hoffmann-La Roche, Janssen, Merck Sharp & Dohme, Otsuka, and Vifor; research funding from AstraZeneca/British Heart Foundation, Kidney Research UK, Medical Research Council, Healthcare Quality Improvement Partnership; honoraria from Amgen and Otsuka. AIA, AF, BLK, RGN, and W-YS reported no relevant disclosures.